Showing 3,261 - 3,280 results of 3,304 for search '"clinical trial"', query time: 0.14s Refine Results
  1. 3261
  2. 3262

    Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti... by Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Thomas Kurz, Marc Remke, Siddhartha Mitra

    Published 2023-01-01
    “…Therefore, targeting epigenetic modifiers for cancer treatment has gained increasing interest, and inhibitors for various epigenetic modulators have been intensively studied in clinical trials. Here, we report a cross-entity, epigenetic drug screen to evaluate therapeutic vulnerabilities in MYC amplified MB, which sensitizes them to macrophage-mediated phagocytosis by targeting the CD47-signal regulatory protein α (SIRPα) innate checkpoint pathway.Methods We performed a primary screen including 78 epigenetic inhibitors and a secondary screen including 20 histone deacetylase inhibitors (HDACi) to compare response profiles in atypical teratoid/rhabdoid tumor (AT/RT, n=11), MB (n=14), and glioblastoma (n=14). …”
    Get full text
    Article
  3. 3263
  4. 3264
  5. 3265

    Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet by Lakshmi Arivazhagan, Sofie Delbare, Robin A. Wilson, Michaele B. Manigrasso, Boyan Zhou, Henry H. Ruiz, Kaamashri Mangar, Ryoko Higa, Emily Brown, Huilin Li, Michael J. Garabedian, Ravichandran Ramasamy, Kathryn J. Moore, Edward A. Fisher, Neil D. Theise, Ann Marie Schmidt

    Published 2025-02-01
    “…The identification of intrinsic, within-sex, diet-dependent disparities underscores the critical need to include both male and female individuals in MAFLD/MASH studies and clinical trials. Impact and implications:: Despite the importance of metabolic dysfunction-associated steatohepatitis (MASH) in impairment of human health, the potential for and mechanisms of sex-dependent responses have yet to be well-studied, particularly with respect to the possible influence of high-fructose corn syrup additives to the diet, which has been linked to metabolic and hepatic disturbances. …”
    Get full text
    Article
  6. 3266

    Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis by Huan Zhang, Jing Huang, Huanji Xu, Nanhao Yin, Nanhao Yin, Liyan Zhou, Liyan Zhou, Jianxin Xue, Jianxin Xue, Jianxin Xue, Min Ren

    Published 2025-01-01
    “…Therefore, a meta-analysis was carried out to assess the efficacy and safety of NIT in patients with non-metastatic pMMR/MSS RC.MethodsPubMed, Embase, Web of Science, the Cochrane Library, ClinicalTrials.gov, ASCO and ESMO were searched to obtain related studies up to July 2024. …”
    Get full text
    Article
  7. 3267
  8. 3268

    Insufficient Evidence to Recommend Shu Mian Capsule in Managing Depression With or Without Comorbid Insomnia: A Systematic Review With Meta-Analysis and Trial Sequential Analysis by Zhao FY, Xu P, Kennedy GA, Jin X, Wang YM, Zhang WJ, Yue LP, Ho YS, Fu QQ, Conduit R

    Published 2025-01-01
    “…Fei-Yi Zhao,1– 3,* Peijie Xu,4,* Gerard A Kennedy,2,* Xiaochao Jin,5,6 Yan-Mei Wang,3 Wen-Jing Zhang,3 Li-Ping Yue,1 Yuen-Shan Ho,7 Qiang-Qiang Fu,8 Russell Conduit2 1Department of Nursing, School of International Medical Technology, Shanghai Sanda University, Shanghai, 201209, People’s Republic of China; 2School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, VIC, 3083, Australia; 3Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People’s Republic of China; 4School of Computing Technologies, RMIT University, Melbourne, VIC, 3000, Australia; 5Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 6Shanghai Jiaotong University School of Nursing, Shanghai, People’s Republic of China; 7School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, People’s Republic of China; 8Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yuen-Shan Ho, School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, People’s Republic of China, Tel +852 2766-6410, Fax +852 2364-9663, Email janice.ys.ho@polyu.edu.hk Qiang-Qiang Fu, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, People’s Republic of China, Tel + 86 021-6569 0520, Fax + 86 021-6569 6249, Email qiangqiang.fu@tongji.edu.cnAim: This systematic review with trial sequential analysis (TSA) aims to evaluate the efficacy and safety of Shu Mian Capsule (SMC), a commercial Chinese polyherbal preparation, for managing depression with or without comorbid insomnia.Methods: Controlled clinical trials assessing SMC against waitlist control, placebo or active controls, or as an adjunct treatment were searched across seven databases. …”
    Get full text
    Article
  9. 3269

    Evaluating the Impact of Pharmacotherapy in Augmenting Quit Rates Among Hispanic Adults in an App-Delivered Smoking Cessation Intervention: Secondary Analysis of a Randomized Contr... by Margarita Santiago-Torres, Kristin E Mull, Brianna M Sullivan, Ana Paula Cupertino, Ramzi G Salloum, Matthew Triplette, Michael J Zvolensky, Jonathan B Bricker

    Published 2025-01-01
    “…Trial RegistrationClinicalTrials.gov NCT02724462; https://clinicaltrials.gov/study/NCT02724462 International Registered Report Identifier (IRRID)RR2-10.1001/jamainternmed.2020.4055…”
    Get full text
    Article
  10. 3270
  11. 3271

    Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizu... by L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

    Published 2025-01-01
    “…Conclusion: Notwithstanding the null findings of this study, positive results of ePRO use in clinical trials and observational studies support the treatment-related symptom monitoring and survival benefits of ePRO utilization.…”
    Article
  12. 3272
  13. 3273
  14. 3274
  15. 3275
  16. 3276
  17. 3277
  18. 3278
  19. 3279
  20. 3280

    Improving the adoption of a school-based nutrition program: findings from a collaborative network of randomised trials by Courtney Barnes, Rachel Sutherland, Lisa Janssen, Jannah Jones, Katie Robertson, Justine Gowland-Ella, Nicola Kerr, Aimee Mitchell, Karen Gillham, Alison L. Brown, Luke Wolfenden

    Published 2025-01-01
    “…Trial registration The trials were prospectively registered with Australia New Zealand Clinical Trials Register: ANZCTR, ACTRN12622000257763, Registered 11/2/2022, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?…”
    Get full text
    Article